Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
BSP Sees Philippine Inflation Easing, Keeps Policy Options Open 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Gold Prices Retreat From Two-Month High as Softer Inflation Eases Fed Rate Hike Bets 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Japan Economy Grows 1.1% in Q2 as Consumer Spending Stalls 
Ferrari Luce EV Sells for Record $40 Million at Charity Auction 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns 
US Dollar Slips as Soft Economic Data Eases Fed Rate Hike Expectations 
Add as a preferred source on Google
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
